ProCE Banner Activity

Advances in Biliary Tract, Gastric, Hepatocellular, and Rectal Cancers at ASCO GI 2022

Conference Coverage
Clinical Thought
In this commentary, experts preview key studies in the management of biliary tract, gastric, hepatocellular, and rectal cancers presented at ASCO GI 2022.

Released: February 08, 2022

Expiration: February 07, 2023

Share

Faculty

Manish A. Shah

Manish A. Shah, MD

Assistant Member, Department of Medicine, Gastrointestinal Oncology
Memorial Sloan-Kettering Cancer Center
Attending Physician, Department of Medicine, Division of Solidy Tumor Oncology
Memorial Hospital
New York, New York

Rachna Shroff

Rachna Shroff, MD, MS

Professor of Medicine
Chief, Section of GI Medical Oncology
Director, UACC Clinical Trials Office
The University of Arizona Cancer Center
Tucson, Arizona

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Manish A. Shah, MD

Assistant Member, Department of Medicine, Gastrointestinal Oncology
Memorial Sloan-Kettering Cancer Center
Attending Physician, Department of Medicine, Division of Solidy Tumor Oncology
Memorial Hospital
New York, New York

Manish A. Shah, MD, has disclosed that he has received funds for research support from Bristol-Myers Squibb and Merck.

Rachna Shroff, MD, MS

Professor of Medicine
Chief, Section of GI Medical Oncology
Director, UACC Clinical Trials Office
The University of Arizona Cancer Center
Tucson, Arizona

Rachna Shroff, MD, has disclosed that she has received consulting fees from AstraZeneca, Boehringer Ingelheim, CAMI, Clovis, Genentech, Incyte, Merck, QED Therapeutics, Servier, Taiho, and Zymeworks and funds for research support from Bayer, Bristol-Myers Squibb, Exelixis, IMV, Loxo, Merck, Novocure, NuCana, Pieris, QED Therapeutics, Rafael, Seagen, and Taiho.